Trial Profile
A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Feb 2018 Status changed from recruiting to discontinued.
- 02 Aug 2011 New trial record